Grazoprevir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Grazoprevir |
| DrugBank ID | DB11575 |
| Brand Names (EU) | Grazoprevir |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.94% |
Approved Indication (EMA)
ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1). For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | chronic hepatitis C virus infection | 99.94% | DL |
| 2 | hepatitis C virus infection | 99.79% | DL |
| 3 | HIV infectious disease | 99.73% | DL |
| 4 | hepatitis B virus infection | 99.73% | DL |
| 5 | hepatitis E virus infection | 99.64% | DL |
| 6 | hepatitis A virus infection | 99.63% | DL |
| 7 | hepatitis, viral, animal | 99.63% | DL |
| 8 | Omsk hemorrhagic fever | 99.62% | DL |
| 9 | Kyasanur forest disease | 99.61% | DL |
| 10 | simian immunodeficiency virus infection | 99.61% | DL |
| 11 | feline acquired immunodeficiency syndrome | 99.61% | DL |
| 12 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.51% | DL |
| 13 | chronic hepatitis B virus infection | 98.17% | DL |
| 14 | obsolete familial combined hyperlipidemia | 97.12% | DL |
| 15 | fibroma of prostate | 96.06% | DL |
| 16 | benign reproductive system neoplasm | 95.84% | DL |
| 17 | Brenner tumor | 95.79% | DL |
| 18 | benign prostate phyllodes tumor | 95.70% | DL |
| 19 | male reproductive organ cancer | 95.03% | DL |
| 20 | prostate leiomyoma | 94.29% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.